TrialBMC cancer2023

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).

Sydney Wolfe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.